Aberrant behavioral effects of a dopamine D1 receptor antagonist and agonist in monkeys: Evidence of uncharted dopamine D1 receptor actions

Biological Psychiatry

Volumn 50, Issue 7, 2001, Pages 501-509

  Peacock, Linda ^a   Gerlach, Jes ^a  

^a Sct Hans Hospital   (Denmark)

Author keywords

Dopamine D1 agonists; Dopamine D1 antagonists; Extrapyramidal side effects; Monkeys; Psychosis; SKF 83822; SKF 83959

Indexed keywords

6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 8 CHLORO 5 (2,3 DIHYDROBENZOFURAN 7 YL) 2,3,4,5 TETRAHYDRO 3 METHYL 1H 3 BENZAZEPIN 7 OL; ADENYLATE CYCLASE; DEXAMPHETAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; PHOSPHOLIPASE C; PLACEBO; QUINPIROLE; RACLOPRIDE; SKF 83822; UNCLASSIFIED DRUG;

ANIMAL MODEL; AROUSAL; ARTICLE; BEHAVIOR DISORDER; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DOSE TIME EFFECT RELATION; DRUG EFFECT; DRUG MECHANISM; DYSKINESIA; DYSTONIA; ENZYME ACTIVATION; LOCOMOTION; MALE; MONKEY; NONHUMAN; PRIORITY JOURNAL; PSYCHOSIS; STEREOTYPY;

2,3,4,5-TETRAHYDRO-7,8-DIHYDROXY-1-PHENYL-1H-3-BENZAZEPINE; ANIMALS; AROUSAL; BEHAVIOR, ANIMAL; CEBUS; CROSS-OVER STUDIES; DOPAMINE; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; DYSKINESIA, DRUG-INDUCED; DYSTONIA; LOCOMOTION; RECEPTORS, DOPAMINE D1; STEREOTYPED BEHAVIOR;

EID: 0035476663     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(01)01189-1     Document Type: Article

References (55)

1. Dopamine receptor subtypes: Beyond the D1/D2 classification
2. Partial and full dopamine D1 receptor agonists in mice and rats: Relation between behavioural effects and stimulation of adenylate cyclase activity in vitro
3. D1 receptor antagonists in schizophrenia
4. Inhibition by dopamine of (Na+ + K+)ATPase activity in neostratal neurons through D1 and D2 dopamine receptor synergism
5. Characteristics of dopamine and B-adrenergic sensitive adenylate cyclases in the frontal cerebral cortex of the rat. Comparative effects of neuroleptics on frontal cortex and striatal dopamine sensitive adenylate cyclases
6. The effects of D1 (NNC 22-0215) and D2 (haloperidol) antagonists in a chronic double-blind placebo controlled trial in cebus monkeys
7. Long-term effects of dopamine D1 and D2 antagonists in vervet monkeys
8. D1 dopamine receptor - The search for a function: A critical evaluation of the D1/D2 receptor classification and its functional implication
9. Molecular diversity of the dopamine receptors
10. Drugs acting at D-1 and D-2 dopamine receptors induce identical purposeless chewing in rats which can be differentiated by cholinergic manipulation
11. An open trial of the D1 antagonist SCH 39166 in six cases of acute psychotic states
12. D1 dopamine receptors in human putamen, frontal cortex and calf retina: Differences in guanine nucleotide regulation of agonist binding and adenylate cyclase stimulation
13. Molecular cloning and expression of the gene for a human D1 dopamine receptor
14. Differential effects of the D1-DA receptor antagonist SCH39166 on positive and negative symptoms of schizophrenia
15. Pharmacological characterization of behavioural responses to SK&F 83959 in relation to "D1-like" dopamine receptors not linked to adenylyl cyclase
16. Grooming and vacuous chewing induced by SK&F 83959, an agonist of dopamine "D1-like" receptors that inhibits dopamine-sensitive adenylyl cyclase
17. Are antagonists of dopamine D1 receptors drugs that attenuate both positive and negative symptoms of schizophrenia? A pilot study in Java monkeys
18. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects
19. Dopamine receptors: Pharmacological and anatomical evidence indicates two distinct dopamine receptor populations are present in the striatum
20. Effect of chronic treatment with NNC 756, a new D-1 receptor antagonist, or raclopride, a D-2 receptor antagonist, in drug-naive Cebus monkeys: Dystonia, dyskinesia and D1/D2 supersensitivity
21. Recent advances in the molecular biology of dopamine receptors
22. Effects of chronic discontinuous and chronic continuous treatment of rats with a dopamine D1 receptor antagonist (NNC-756)
23. Differential anti-parkinsonian effects of benzazepine D1 dopamine agonists with varying efficacies in the MPTP-treated common marmoset
24. Selective dopamine antagonist pretreatment on the antiparkinsonian effects of benzazepine D1 dopamine agonists in rodent and primate models of Parkinson's disease - The differential effects of D1 dopamine agonists in the primate
25. Multiple human D5 dopamine receptor genes: A functional receptor and two pseudogenes
26. SCH23390, a potential benzazepine antipsychotic with unique interactions on dopaminergic systems
27. Drug-induced oral dyskinesias in rats after traditional and new neuroleptics
28. NNC 01-687, a selective dopamine D1 receptor antagonist, in the treatment of schizophrenia
29. Lack of apparent antipsychotic effect of the D1 dopamine receptor antagonist SCH39166 in acutely ill schizophrenic patients
30. Multiple receptors for dopamine
31. Selective D1 and D2 receptor manipulation in Cebus apella monkeys: Relevance for dystonia and dykinesia in humans
32. Commentary: Dopamine-sensitive adenylate cyclase as a receptor site
33. Cholera toxin sensitive 3′,5′-cyclic adenosine monophosphate and calcium signals of the human dopamine-D1 receptor: Selective potentiation by protein kinase A
34. Long-term treatment with low doses of the D1 antagonist NNC 756 and the D2 antagonist raclopride in monkeys previously exposed to dopamine antagonists
35. Chronic treatment with the D1 receptor antagonist, SCH 23390, and the D2 receptor antagonist, raclopride, in cebus monkeys withdrawn from previous haloperidol treatment: Extrapyramidal syndromes and dopaminergic supersensitivity
36. Biochemical and functional studies of D-1 dopamine receptors: Multiple forms of the D1 dopamine receptor: Its linkage to adenylate cyclase and psychopharmacological effects
37. Coupling of dopamine D1 recognition sites with adenylate cyclase in nuclei accumbens and caudate of schizophrenics
38. Pharmacological characterization of D1 and D2 dopamine receptors in rat limbocortical areas. I. Frontal cortex
39. Effects of several partial dopamine D2 receptor agonists in Cebus apella monkeys previously treated with haloperidol
40. D-1 antagonists in animal models and in schizophrenia: Potential antipsychotic effects and extrapyramidal side effects
41. New and old antipsychotics versus clozapine in a monkey model: Adverse effects and antiamphetamine effects
42. Chronic dopamine D1, dopamine D2 and combined dopamine D1 and D2 antagonist treatment in Cebus apella monkeys: Antiamphetamine effects and extrapyramidal side effects
43. The effects of dopamine D1 and D2 receptor agonists and antagonists in monkeys withdrawn from long-term neuroleptic treatment
44. Dopamine activation of the arachidonic acid cascade as a basis for D1/D2 receptor synergism
45. Comparative distributions of dopamine D1 and D2 receptors in the cerebral cortex of rats, cats and monkeys
46. Relationship between behavioural activation and adenylate cyclase activity induced by the dopamine D1 receptor agonists SK&F 80723, 83565 and 83959
47. A phosphoinositide-linked dopamine D1 receptor mediates repetitive jaw movement in rats
48. Induction of oral dyskinesia in naive rats by D1 stimulation
49. Identification of a D1 dopamine receptor, not linked to adenylate cyclase, on lactotroph cells
50. Dopamine receptor pharmacology
51. The central effects of a novel dopamine agonist
52. Molecular biology of dopamine receptors
53. Cloning of the gene for a human D5 receptor with higher affinity for dopamine than D1
54. Evidence for a distinct D1-like receptor that couples to activation of phosphoinositide metabolism in brain
55. The D1 dopamine receptor antagonist SCH 23390 can exert D1 agonist-like effects on rat nucleus accumbens neurons